Probiotics show IBS benefits for children: Study

by on August 23, 2010

Probiotics show IBS benefits for children: Study
“There is evidence that some probiotics […] have a beneficial role in the dietary management of children and teenagers suffering with IBS,” said Stefano Guandalini, MD, lead researcher and professor at the University of Chicago.

Read more on Nutraingredients.com

{ 0 comments }

Highlights from the Mayo Clinic Health Letter August issue: Chronic Constipation; Improving Symptoms of IBS; and …

by on August 23, 2010

Highlights from the Mayo Clinic Health Letter August issue: Chronic Constipation; Improving Symptoms of IBS; and …
ROCHESTER, Minn.–(BUSINESS WIRE)–Here are highlights from the August issue of Mayo Clinic Health Letter. You may cite this publication as often as you wish. Reprinting is allowed for a fee. Mayo Clinic Health Letter attribution is required. Include the following subscription information as your editorial policies permit: Visit www.HealthLetter.MayoClinic.com for …

Read more on Business Wire

{ 0 comments }

New Procedure Offers Hope to Those with Irritable Bowel Syndrome

August 23, 2010

New Procedure Offers Hope to Those with Irritable Bowel Syndrome As many as one in every five American adults suffers the symptoms of irritable bowel syndrome (IBS), an often-debilitating condition that can cause abdominal pain or cramps, bloating, gas, diarrhea and constipation. Read more on PRWeb via Yahoo! News

Read the full article →

VSL#3® Probiotic Shown Effective in Dietary Management of Children With Irritable Bowel Syndrome

August 23, 2010

VSL#3® Probiotic Shown Effective in Dietary Management of Children With Irritable Bowel Syndrome GAITHERSBURG, Md., Aug. 16 /PRNewswire-USNewswire/ — New data show that VSL#3, a high-potency probiotic medical food, provides effective dietary management of children affected with irritable bowel syndrome (IBS). Until recently, little has been done to understand the role of probiotics in the [...]

Read the full article →

No middle ground for ‘Fingers of Death’

August 23, 2010

No middle ground for ‘Fingers of Death’ You’ll either love the idea or hate it In a recent interview Rick Moody described The Four Fingers of Death as “a 900-page comic novel about a disembodied arm set in the desert in 2026.” And maybe that’s all you need to know about it because, let’s face [...]

Read the full article →

NEWS IN BRIEF – 8/22/10

August 23, 2010

NEWS IN BRIEF – 8/22/10 Animal abuse case gets dismissed Read more on The Ironton Tribune

Read the full article →

Proof that a gut-wrenching complaint — irritable bowel syndrome — is not in your head

August 23, 2010

Proof that a gut-wrenching complaint — irritable bowel syndrome — is not in your head Irritable bowel syndrome makes life miserable for those affected, an estimated ten percent or more of the population. What further irritates many sufferers is that they often are labeled as hypochondriacs, since physical causes have never been identified — until [...]

Read the full article →

Proof That Irritable Bowel Syndrome Is Not In Your Head

August 23, 2010

Proof That Irritable Bowel Syndrome Is Not In Your Head Irritable bowel syndrome makes life miserable for those affected — an estimated ten percent or more of the population. And what irritates many of them even more is that they often are labeled as hypochondriacs, since physical causes for irritable bowel syndrome have never been [...]

Read the full article →

Treatment of Non-Constipation Irritable Bowel Syndrome

August 23, 2010

Treatment Options of Non-Constipation Irritable Bowel Syndrome Announced Salix Announces FDA Acceptance for Filing and Priority Review Designation For XIFAXAN550 sNDA For the Treatment of Non-Constipation Irritable Bowel Syndrome PDUFA Action Date Designated as December 7, 2010 RALEIGH, N.C., Aug 09, 2010 (BUSINESS WIRE) — Salix Pharmaceuticals, Ltd. /quotes/comstock/15*!slxp/quotes/nls/slxp (SLXP 40.42, +0.22, +0.55%) today announced [...]

Read the full article →

FDA accepts Salix’s XIFAXAN550 sNDA for Priority Review

August 10, 2010

FDA accepts Salix’s XIFAXAN550 sNDA for Priority Review Salix Pharmaceuticals, Ltd. today announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Company’s efficacy supplement to the New Drug Application (NDA) for XIFAXAN® (rifaximin) 550 mg tablets for the proposed indication of treatment of non-constipation irritable bowel syndrome (Non-C IBS) and [...]

Read the full article →

← Previous Entries